Related references
Note: Only part of the references are listed.Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
Sergey V. Tokalov et al.
BMC CANCER (2010)
Differential binding of p53 and nutlin to MDM2 and MDMX Computational studies
Thomas Leonard Joseph et al.
CELL CYCLE (2010)
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery
Grzegorz M. Popowicz et al.
CELL CYCLE (2010)
Mdm2-mediated ubiquitylation: p53 and beyond
J-C Marine et al.
CELL DEATH AND DIFFERENTIATION (2010)
The multiple levels of regulation by p53 ubiquitination
J. T. Lee et al.
CELL DEATH AND DIFFERENTIATION (2010)
Patented inhibitors of p53-Mdm2 interaction (2006-2008)
Lutz Weber
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX
Jason Phan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways
Tongsen Zheng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
A Medicinal Chemist's Guide to Molecular Interactions
Caterina Bissantz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Role of Mdm4 in drug sensitivity of breast cancer cells
S. Lam et al.
ONCOGENE (2010)
The p53 orchestra: Mdm2 and Mdmx set the tone
Mark Wade et al.
TRENDS IN CELL BIOLOGY (2010)
Apamin as a Template for Structure-Based Rational Design of Potent Peptide Activators of p53
Chong Li et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
Signaling to p53: Ribosomal Proteins Find Their Way
Yanping Zhang et al.
CANCER CELL (2009)
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx
Anna Czarna et al.
CELL CYCLE (2009)
The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior
Yan Liu et al.
CELL CYCLE (2009)
Dimerization of the core domain of the p53 family A computational study
Arumugam Madhumalar et al.
CELL CYCLE (2009)
Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes
Joerg Kallen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Rapid and Efficient Hydrophilicity Tuning of p53/mdm2 Antagonists
Stuti Srivastava et al.
JOURNAL OF COMBINATORIAL CHEMISTRY (2009)
Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction
John G. Allen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Marzena Pazgiera et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
The expanding universe of p53 targets
Daniel Menendez et al.
NATURE REVIEWS CANCER (2009)
Structural biology of the tumor suppressor p53
Andreas C. Joerger et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Sanjeev Shangary et al.
Annual Review of Pharmacology and Toxicology (2008)
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain
Grzegorz M. Popowicz et al.
CELL CYCLE (2008)
Small molecular weight protein-protein interaction antagonists -: an insurmountable challenge?
Alexander Doemling
CURRENT OPINION IN CHEMICAL BIOLOGY (2008)
Multiple peptide conformations give rise to similar binding affinities: Molecular simulations of p53-MDM2
Shubhra Ghosh Dastidar et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Turning a scorpion toxin into an antitumor miniprotein
Chong Li et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines
M. Kitagawa et al.
ONCOGENE (2008)
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Sanjeev Shangary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Targeting MDM2 and MDMX in retinoblastoma
Nikia A. Laurie et al.
CURRENT CANCER DRUG TARGETS (2007)
Molecular basis for the inhibition of p53 by Mdmx
Grzegorz M. Popowicz et al.
CELL CYCLE (2007)
Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX
Baoli Hu et al.
CANCER RESEARCH (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
MDMX: from bench to bedside
Jean-Christophe W. Marine et al.
JOURNAL OF CELL SCIENCE (2007)
MDM2 inhibitors for cancer therapy
Lyubomir T. Vassilev
TRENDS IN MOLECULAR MEDICINE (2007)
Small molecule protein-protein inhibitors for the p53-MDM2 interaction
Anna S. Dudkina et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Modeling the therapeutic efficacy of p53 restoration in tumors
Carla P. Martins et al.
CELL (2006)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin
Baoli Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Determinants of specificity of MDM2 for the activation domains of p53 and p65: Proline27 disrupts the MDM2-binding motif of p53
Susan Carr Zondlo et al.
BIOCHEMISTRY (2006)
Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design
Daniel J. Parks et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Discovery of pyrroloimidazoles as agents stimulating neurite outgrowth
Barbara Beck et al.
QSAR & COMBINATORIAL SCIENCE (2006)
Benzodiazepinedione inhibitors of the Hdm2 : p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
HK Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Structure-based design of potent non-peptide MDM2 inhibitors
K Ding et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
BL Grasberger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
High-density miniaturized thermal shift assays as a general strategy for drug discovery
MW Pantoliano et al.
JOURNAL OF BIOMOLECULAR SCREENING (2001)
Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53
C García-Echeverría et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
